Blood:与多发性骨髓瘤患者感染新冠病毒预后的相关因素

2020-11-25 MedSci原创 MedSci原创

多发性骨髓瘤(MM)患者发病和死亡的主要原因是感染。因此,在COVID-19大流行期间,人们都非常关注感染COVID-19的MM患者的预后。

多发性骨髓瘤(MM)患者发病和死亡的主要原因是感染。因此,在COVID-19大流行期间,人们都非常关注感染COVID-19的MM患者的预后。

这项回顾性研究总结了650例感染了COVID-19的浆细胞疾病患者的基线特征和临床预后。

不同国家的死亡率

患者的中位年龄为69岁,几乎都(96%)是MM。约36%的患者为近两年确诊(2019年-2020年),还有54%的患者已进行了一线治疗。33%的患者已死亡,存在很明显的地域差异,不同地域之间住院患者的死亡率浮动在27%-57%。

死亡相关风险因素

单因素分析发现年龄、ISS3、高危疾病、肾病和控制不良的骨髓瘤(活动性或进展性)以及一种或多种合并症为高死亡率的危险因素。骨髓移植,即使是在COVID-19感染内进行的,和预后都没有明显的相关性;其他抗MM治疗也与预后无相关性。多变量分析发现,只有年龄、高危型MM、肾病和MM控制不佳仍然是COVID-19感染不良预后的独立预测因素。

总而言之,在COVID-19大流行期间,MM患者的管理需要仔细考虑患者和疾病相关因素,以降低感染COVID-19的风险,同时治疗感染COVID-19的MM患者时,需适当兼顾两种疾病。

原始出处:

Ajai Chari, et al. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. Blood. November 06, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890188, encodeId=0ba5189018876, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Jul 02 06:11:41 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457532, encodeId=ce57145e53232, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Fri Nov 27 09:11:41 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902335, encodeId=2fc39023358b, content=希望有动态跟进, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210113/49ccb25556f441c0850bdefc3c8432be/5f80a486ed9f449ea166396944dbcc90.jpg, createdBy=b51f5435872, createdName=慕尔, createdTime=Thu Nov 26 00:16:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028816, encodeId=da3f102881618, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Nov 25 21:11:41 CST 2020, time=2020-11-25, status=1, ipAttribution=)]
    2021-07-02 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890188, encodeId=0ba5189018876, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Jul 02 06:11:41 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457532, encodeId=ce57145e53232, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Fri Nov 27 09:11:41 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902335, encodeId=2fc39023358b, content=希望有动态跟进, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210113/49ccb25556f441c0850bdefc3c8432be/5f80a486ed9f449ea166396944dbcc90.jpg, createdBy=b51f5435872, createdName=慕尔, createdTime=Thu Nov 26 00:16:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028816, encodeId=da3f102881618, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Nov 25 21:11:41 CST 2020, time=2020-11-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890188, encodeId=0ba5189018876, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Jul 02 06:11:41 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457532, encodeId=ce57145e53232, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Fri Nov 27 09:11:41 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902335, encodeId=2fc39023358b, content=希望有动态跟进, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210113/49ccb25556f441c0850bdefc3c8432be/5f80a486ed9f449ea166396944dbcc90.jpg, createdBy=b51f5435872, createdName=慕尔, createdTime=Thu Nov 26 00:16:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028816, encodeId=da3f102881618, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Nov 25 21:11:41 CST 2020, time=2020-11-25, status=1, ipAttribution=)]
    2020-11-26 慕尔

    希望有动态跟进

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1890188, encodeId=0ba5189018876, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Jul 02 06:11:41 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457532, encodeId=ce57145e53232, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Fri Nov 27 09:11:41 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902335, encodeId=2fc39023358b, content=希望有动态跟进, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210113/49ccb25556f441c0850bdefc3c8432be/5f80a486ed9f449ea166396944dbcc90.jpg, createdBy=b51f5435872, createdName=慕尔, createdTime=Thu Nov 26 00:16:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028816, encodeId=da3f102881618, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Nov 25 21:11:41 CST 2020, time=2020-11-25, status=1, ipAttribution=)]
    2020-11-25 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

Lancet oncol:RAF-MEK抑制剂在携带RAS/RAF突变的多种肿瘤中的抗肿瘤活性

CH5126766(又名VS-6766,曾用名RO5126766)是一种新型的MEK-pan-RAF抑制剂,已知在多种实体肿瘤中具有抗肿瘤活性;但该药物的推广受毒性限制。现本研究旨在评估CH51267

Clin Cancer Res:多发性骨髓瘤:来那度胺的“大剂量”累觉不爱

对于多发性骨髓瘤,大剂量化疗和自体造血干细胞移植(ASCT)继以来那度胺(10-15 mg/天)维持治疗(LenMT)被认为是标准疗法。然而,根据不良反应而降低剂量常有发生,随时间推移而达到的LenM

Lancet:塞利尼索、硼替佐米和地塞米松联合用于一线治疗失败的多发性骨髓瘤患者

对于先前接受过1-3种治疗方案的多发性骨髓瘤患者,每周1次塞利尼索、硼替佐米和地塞米松联合治疗可延长患者无进展生存期

Blood:多发性骨髓瘤克隆进化和扩散的特征

克隆进化驱动多发性骨髓瘤(MM)的肿瘤进展、扩散和复发,大多数患者死于复发疾病。这一多阶段过程需要肿瘤细胞进入血液循环、渗出和定植到远处骨髓(BM)中。

JCO:18F-FDG–PET/CT定义多发性骨髓瘤代谢完全缓解的标准

18F-FDG–PET/CT是目前检测多发性骨髓瘤(MM)患者骨髓(BM)外最小残留病灶(MRD)状态的标准方法。该研究旨在定义治疗后PET完全代谢缓解的标准,联合分析了两个独立的欧洲随机